ABSTRACT
The aim was (1) to perform an up-to-date systematic review of the male circumcision (MC) literature and (2) to determine the number of adverse medical conditions prevented by early MC in Australia. Searches of PubMed using "circumcision" with 39 keywords and bibliography searches yielded 278 publications meeting our inclusion criteria. Early MC provides immediate and lifetime benefits, including protection against: urinary tract infections, phimosis, inflammatory skin conditions, inferior penile hygiene, candidiasis, various STIs, and penile and prostate cancer. In female partners MC reduces risk of STIs and cervical cancer. A risk-benefit analysis found benefits exceeded procedural risks, which are predominantly minor, by approximately 200 to 1. It was estimated that more than 1 in 2 uncircumcised males will experience an adverse foreskin-related medical condition over their lifetime. An increase in early MC in Australia to mid-1950s prevalence of 85% from the current level of 18.75% would avoid 77,000 cases of infections and other adverse medical conditions over the lifetime for each annual birth cohort. Survey data, physiological measurements, and the anatomical location of penile sensory receptors responsible for sexual sensation indicate that MC has no detrimental effect on sexual function, sensitivity or pleasure. US studies found that early infant MC is cost saving. Evidence-based reviews by the AAP and CDC support early MC as a desirable public health measure. Although MC can be performed at any age, early MC maximizes benefits and minimises procedural risks. Parents should routinely be provided with accurate, up-to-date evidence-based information in an unbiased manner early in a pregnancy so that they have time to weigh benefits and risks of early MC and make an informed decision should they have a son. Parental choice should be respected. A well-trained competent practitioner is essential and local anaesthesia should be routinely used. Third party coverage of costs is advocated.
ABSTRACT
Background. Hypothyroidism and raised thyroid antibody levels have been associated with adverse obstetrical outcomes. Several studies have investigated causal associations, but results have been inconsistent and few studies have reported the effects of thyroxine replacement therapy on pregnancy outcomes in hypothyroid patients. Objective. The primary study objective was to determine the outcome of pregnancies in women diagnosed with overt and subclinical hypothyroidism (SCH) (serum TSH > 2.5 mIU/L) and those with elevated circulating thyroid autoantibody levels in the first trimester of pregnancy and after the institution of appropriate thyroxine replacement therapy to maintain the serum TSH ≤ 2.5 mIU/L. Study Design. This prospective observational study was undertaken between 2013 and 2016. Blood samples were taken from 1025 women at presentation for thyroid stimulating hormone (TSH), anti-thyroglobulin antibodies (TGAb), and thyroid peroxidase antibodies (TPOAb). Those with a TSH > 2.5 mIU/L were treated with thyroxine and managed appropriately to ensure that the TSH was maintained ≤2.5 mIU/L. Outcomes in these patients were compared to those in euthyroid patients. Maternal antenatal complications and perinatal outcomes were recorded. Results. There were a total of 1025 patients of whom 382 (37.5%) were nulliparous. 10.1% had a TSH level > 2.5 mIU/L and 18.2% had at least one raised thyroid antibody level. No differences in adverse outcomes of pregnancy were evident in women treated for SCH or overt hypothyroidism compared to the euthyroid group. There was also no association between raised thyroid antibodies and adverse pregnancy outcomes in either group. Conclusion. There were no adverse outcomes of pregnancy found in pregnant women who had been diagnosed and treated with thyroxine for SCH at the time of presentation when compared to euthyroid patients. There was also no relationship with thyroid antibodies and adverse pregnancy outcomes in the two groups. It is not possible to unequivocally advocate for thyroxine replacement in pregnant women with subclinical and overt hypothyroidism until large scale randomized controlled trials are performed.
ABSTRACT
BACKGROUND: Hypothyroidism in pregnancy is associated with adverse obstetrical events and neurodevelopmental disorders in infants. The prevalence of thyroid dysfunction during pregnancy in Australia is not well documented, and universal screening remains questionable. AIM: To assess the prevalence of thyroid dysfunction and positive thyroid antibodies and review the indications for universal screening of thyroid function in pregnancy. MATERIALS AND METHODS: The prospective observational study was undertaken between 2009 and 2014. Thyroid-stimulating hormone (TSH), free thyroxine (FT4) levels, thyroglobulin antibodies (TgAb) and thyroid peroxidase antibodies (TPOAb) were measured in 1069 women at booking-in. RESULTS: One hundred and three women, (9.6%), exhibited subclinical hypothyroidism, with TSH levels >2.5mIU/l. Eighty-seven women (8.1%) had TSH levels > 2.5 and ≤5 mIU/l. Of these, 41.4% (36 patients) were positive for TPOAb. Twelve women (1.5%) had a TSH >5 and ≤10 mIU/l with 66.7% (8 patients) positive for TPOAb. Four patients (0.4%) had a TSH level >10 mIU/l with 50% (2 patients) positive for TPOAb. Positive thyroid antibodies were detected in 258 patients (24.13%). Although statistically significant, the rank correlations between TSH and TPOAb (r = 0.08, P = 0.023) and TgAb (r = -0.081, P = 0.021) were weak. Similarly, weak rank correlations were observed between TSH and age (r = -0.095), parity (r = -0.081) and weight (r = 0.089). CONCLUSION: A high prevalence of subclinical hypothyroidism and positive thyroid antibodies exists in this cohort, as well as unsuspected chemical hypothyroidism, providing a strong case for universal screening with TSH and the consideration of thyroid antibody testing of all Australian pregnant women.
